Semaglutide
ContestedGLP-1
Our read of public sources: some pharmacies compound it under a legal theory — a differentiated-formulation argument, or in anticipation of a pending committee recommendation — that no court ruling or final FDA rule has settled either way. We're flagging this as actively debated, not as a green or red light. This is not a legal determination; verify independently before relying on it.
Not legal advice. Every status on this page is our own reading of public FDA guidance, shortage listings, and committee materials — it has not been reviewed by an attorney and is not a legal determination. "Contested" means pharmacies and regulators publicly disagree, not that we're resolving the disagreement. Verify independently, and check with counsel, before relying on any entry here.
Current status
Shortage resolved Feb 2025, ending the compounding exception for most pharmacies. FDA has proposed permanently excluding semaglutide from the 503B bulk substances list (comment period open through June 29, 2026). Some pharmacies continue compounding under differentiated-formulation theories similar to tirzepatide.
Shortage-list history: Removed from FDA shortage list February 2025.
Last changed: 2026-06-29